Management of diabetes associated with nephrotic syndrome: Therapeutic potential of dapagliflozin for protracted volume retention

Drug Target Insights

Volumn 9, Issue , 2015, Pages 29-31

  Imai, Toshimi ^a   Akimoto, Tetsu ^a   Ito, Chiharu ^a   Masuda, Takahiro ^a   Nagata, Daisuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Dapagliflozin; Diabetes; Furosemide; Nephrotic syndrome; SGLT 2

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALOGLIPTIN; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHLORIDE; CREATININE; DAPAGLIFLOZIN; FUROSEMIDE; HEMOGLOBIN A1C; IRBESARTAN; NITROGEN; POTASSIUM; ROSUVASTATIN; SODIUM; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARM EDEMA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHLORIDE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ERYTHROCYTE; FACE EDEMA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LABORATORY TEST; LEG EDEMA; LEG SWELLING; MIDDLE AGED; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHYSICAL EXAMINATION; PLEURA EFFUSION; POTASSIUM BLOOD LEVEL; PROTEINURIA; SODIUM BLOOD LEVEL; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINARY EXCRETION; URINE RETENTION;

EID: 84947060967     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.S31710     Document Type: Article

References (17)

1. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotrans­port inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657.
2. Onoyama K, Kumagai H, Fujishima M. Hemodynamic and volume changes by ultrafiltration in refractory edema of diabetic nephrotic syndrome with severe renal insufficiency. Clin Nephrol. 1987;27(1):21–25.
3. Davenport A. Ultrafiltration in diuretic-resistant volume overload in nephrotic syndrome and patients with ascites due to chronic liver disease. Cardiology. 2001;96(3–4):190–195.
4. Brater DC. Diuretic resistance: mechanisms and therapeutic strategies. Cardiology. 1994;84(2):57–67.
5. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22(1):104–112.
6. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12(2):78–89.
7. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375–393.
8. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012;32(1):80–94.
9. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–862.
10. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapa­gliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513–519.
11. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–545.
12. Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of hydrochloro­thiazide on the pharmacokinetics, pharmacodynamics, and tolerability of cana­gliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014;36(5):698–710.
13. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a sys­tematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–275.
14. Meltzer JI, Keim HJ, Laragh JH, Sealey JE, Jan KM, Chien S. Nephrotic syndrome: vasoconstriction and hypervolemic types indicated by renin-sodium profiling. Ann Intern Med. 1979;91(5):688–696.
15. Wilding JP, Norwood P, T’joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–1662.
16. Thomas MC, Jandeleit-Dahm K, Bonnet F. Beyond glycosuria: exploring the intrarenal effects of SGLT-2 inhibition in diabetes. Diabetes Metab. 2014;40(6):S17–S22.
17. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int. 2011;79(120):S20–S27.